Skip to main content

Table 1 Clinical characteristics of heart failure patients

From: Plasma fibroblast activation protein is decreased in acute heart failure despite cardiac tissue upregulation

 

Cardiac tissue

Plasma

 

mRNA-Seq

ncRNA-Seq

Western Blot

ELISA

 
 

HF (n = 26)

HF (n = 42)

HF (n = 26)

Acute HF (n = 48)

Chronic HF (n = 15)

P value

Age (years)

53 ± 9

53 ± 10

50 ± 13

71 ± 14

57 ± 10

 < 0.001

Gender male (%)

96

93

85

67

87

0.195

Non-ischemic dilated cardiomyopathy (%)

50

48

50

46

40

0.772

Ischemic cardiomyopathy (%)

50

52

50

54

60

NYHA class

III–IV

III–IV

III–IV

I–IV

III–IV

0.001

BMI (kg/m2)

27 ± 5

26 ± 4

26 ± 5

30 ± 5

25 ± 5

0.002

Hemoglobin (mg/dL)

14 ± 3

13 ± 2

14 ± 3

12 ± 2

14 ± 2

0.002

Hematocrit (%)

40 ± 7

40 ± 6

40 ± 6

38 ± 6

43 ± 7

0.009

Total cholesterol (mg/dL)

155 ± 39

161 ± 45

154 ± 52

129 ± 33

116 ± 29

0.207

Prior hypertension (%)

25

32

36

82

67

0.283

Prior smoking (%)

71

72

64

50

40

0.561

Diabetes mellitus (%)

29

29

26

46

20

0.129

Hypercholesterolemia (%)

13

19

22

60

53

0.765

LVEF (%)

21 ± 8

21 ± 7

24 ± 8

30 ± 13

21 ± 10

0.035

LVESD (mm)

66 ± 12

61 ± 12

61 ± 12

44 ± 13

59 ± 11

0.001

LVEDD (mm)

74 ± 11

69 ± 12

69 ± 12

56 ± 10

68 ± 10

 < 0.001

  1. HF Heart failureNYHA New York Heart Association, BMI body mass index, LVEF left ventricular ejection fraction, LVESD left ventricular end-systolic diameter, LVEDD left ventricular end-diastolic diameter
  2. P value is the comparison between acute HF and chronic HF in plasma samples